Loading...
XSHE300439
Market cap506mUSD
Jan 10, Last price  
9.70CNY
1D
-2.71%
1Q
-9.60%
Jan 2017
-67.87%
IPO
-33.20%
Name

MedicalSystem Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300439 chart
P/E
14.48
P/S
1.97
EPS
0.67
Div Yield, %
1.34%
Shrs. gr., 5y
2.13%
Rev. gr., 5y
-9.67%
Revenues
1.89b
-24.23%
192,520,105327,742,449432,061,495597,849,201683,141,1601,059,147,0702,584,187,5653,135,122,9193,133,447,6972,302,032,4212,251,532,2062,489,086,2161,885,869,216
Net income
257m
+29.23%
53,328,06891,734,676103,529,869137,684,356161,267,521174,494,721229,700,185241,172,0820299,480,578179,488,034198,527,038256,551,420
CFO
634m
+12.20%
49,824,50046,778,385100,063,948116,510,814177,548,0862,453,7050418,803,231601,170,720912,074,949515,482,463564,665,289633,532,150
Dividend
Jun 07, 20240.134 CNY/sh
Earnings
May 23, 2025

Profile

Medicalsystem Biotechnology Co., Ltd. provides clinical diagnostics reagents and instruments in China. The company offers PCR kit, antibody test kit, antigen test kit, and nucleic acid reagent for COVID-19; automated biochemistry analyzers and bio reagents; hematology analyzers; urine analyzers; glycated hemoglobin analyzer; POCT; and chemiluminescene immunoassay analyzers. It also provides healthcare services. The company was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Medicalsystem Biotechnology Co., Ltd. in January 2017. Medicalsystem Biotechnology Co., Ltd. was founded in 2003 and is based in Ningbo, China.
URL
https://www.nbmksw.com/
IPO date
Apr 22, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,885,869
-24.23%
2,489,086
10.55%
Cost of revenue
1,430,160
2,075,970
Unusual Expense (Income)
NOPBT
455,709
413,116
NOPBT Margin
24.16%
16.60%
Operating Taxes
36,179
18,102
Tax Rate
7.94%
4.38%
NOPAT
419,530
395,014
Net income
256,551
29.23%
198,527
10.61%
Dividends
(49,881)
(36,385)
Dividend yield
1.12%
0.81%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
50,054
297,631
Long-term debt
47,192
60,979
Deferred revenue
2,321
Other long-term liabilities
11,348
11,620
Net debt
(1,079,675)
(610,503)
Cash flow
Cash from operating activities
633,532
564,665
CAPEX
(280,369)
Cash from investing activities
(200,781)
Cash from financing activities
(294,382)
FCF
506,669
469,734
Balance
Cash
964,882
886,578
Long term investments
212,039
82,535
Excess cash
1,082,628
844,659
Stockholders' equity
1,476,212
1,452,320
Invested Capital
1,709,063
1,981,884
ROIC
22.73%
19.39%
ROCE
16.05%
14.44%
EV
Common stock shares outstanding
382,913
383,000
Price
11.61
-0.77%
11.70
-45.10%
Market cap
4,445,615
-0.79%
4,481,098
-43.76%
EV
3,357,698
3,879,972
EBITDA
625,340
604,789
EV/EBITDA
5.37
6.42
Interest
10,910
15,634
Interest/NOPBT
2.39%
3.78%